Amit Kumar Nayak (M. Pharm, Ph.D) is currently working as Professor at School of Pharmaceutical Sciences,Siksha ‘O' Anusandhan (Deemed to be University), Odisha, India. He has earned his PhD from IFTM University, Moradabad, Uttar Pradesh, India. He has over 14 years of research experiences in the field of pharmaceutics, especially in the development and characterization of novel biopolymeric and nanostructured drug delivery systems. Till date, he has authored more than 138 research and review publications in various high-impact peer-reviewed journals and 135 book chapters. He has edited/authored 23 international books to his credit. Dr. Nayak has presented his research work at several conferences. He has received University Foundation Day Research Award, 2019 and 2022 by Biju Patnaik University of Technology, Odisha. Dr. Nayak is a life member of the Association of Pharmaceutical Teachers of India (APTI) and a registered pharmacist.Dr. Amal Kumar Dhara has over 27 years of teaching and research experience in Pharmacology and Toxicology, with expertise in neuropharmacology, anti-inflammatory, antiulcer, and free radical scavenging activities of Indian medicinal plants. He earned his PhD in Pharmaceutical Sciences from Jadavpur University, Kolkata, West Bengal, India. Dr. Dhara currently serves as Head of the Department (Pharmacy) at Contai Polytechnic, Government of West Bengal, India. He has previously worked as a Production Executive at M/S Deys Medical Stores Mfg (UP) Ltd., Uttar Pradesh, for over three years. Dr. Dhara has authored more than ten research and review papers in reputed journals, along with fifteen book chapters and five books. He has presented his work at national and international conferences and is a life member of the Indian Pharmaceutical Association and Indian Pharmacological Society, as well as a registered pharmacist.

• SECTION I: INTRODUCTION1. Introduction to SARS-CoV-2 therapySECTION II: VIRAL INFECTIONS, TRANSMISSION, AND TESTING2. Pathophysiology of SARS-CoV-2 viral infections3. Quantification of SARS-CoV-2 in wastewater4. Understanding interaction between SARS-CoV-2 spike receptor-binding domain and surface receptors for drug design against SARS-CoV-25. Mutations of SARS-CoV-26. Resistance of SARS-CoV-2 to therapeutic agents7. Adaptation of SARS-CoV-2 to immune system8. Impact of comorbidity in SARS- CoV-2 infection9. Role of T Cells in the SARS-CoV-2 infection10. Rapid detection of SARS-CoV-2 infectionSECTION III: ANTIVIRAL AGENTS AND THERAPEUTICS11. Challenges in designing SARS-CoV-2 antiviral agents12. Innate and adaptive immune responses in SARS-CoV-2 infection13. The role of Vitamin D in the SARS-CoV-2 infection14. Novel approach towards therapeutic regimen against SARS-CoV-2 infection15. Development of targeted antiviral with particular reference to SARS-CoV-216. Development of SARS-CoV-2 vaccine17. Development of mRNA vaccines and modification of formulation for administering in multiple routes against SARS-CoV-218. Role of natural polysaccharides against COVID-1919. Monoclonal antibodies cocktail for the treatments of COVID-1920. Importance of nutraceuticals in fighting SARS-CoV-221. Herbal drugs to combat SARS-CoV-2 virus22. Role of plasma therapy in the management of SARS-CoV-2 viral infections23. Intranasal vaccines for SARS-CoV-224. Preclinical studies of a receptor – binding domain (RBD) –based recombinant protein vaccine on animal model (with particular reference to SARS- CoV-2)SECTION IV: OTHER RELATED TOPICS25. Mucormycosis – a serious problem in COVID-19 patients26. Clinical trials and regulatory considerations of SARS-CoV-2 antiviral agents27. Market overview of SARS-CoV-2 antiviral drugs28. Future perspectives of SARS-CoV-2 antiviral therapy